Literature DB >> 1460288

Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration.

M Ebisawa1, B S Bochner, S N Georas, R P Schleimer.   

Abstract

IL-1 beta promotes adhesiveness in human umbilical vein endothelial cells (HuVEC) for eosinophils through expression of adhesion molecules including intercellular adhesion molecules-1 (ICAM-1), E-selectin, and vascular cell adhesion molecule-1 (VCAM-1). Using an in vitro endothelial monolayer system, we examined whether IL-1 beta or TNF-alpha can promote eosinophil transendothelial migration. We also evaluated the contributions of ICAM-1, E-selectin, VCAM-1, leukocyte adhesion complex (CD11/18), and very late Ag-4 (CD11b/18) (VLA-4) in this process using blocking mAb, and determined the changes in expression of CD11b and L-selectin on eosinophils that had undergone transmigration. IL-1 beta and TNF-alpha treatment of HuVEC (4 h, 5 ng/ml) induced significant transendothelial migration of eosinophils (a 4.1 +/- 0.4-fold (IL-1 beta) and 2.0 +/- 0.9-fold (TNF-alpha) increase from the spontaneous value of 3.2 +/- 0.3%). Increased CD11b expression and shedding of L-selectin were observed on eosinophils following IL-1 beta-induced eosinophil transendothelial migration. Studies with mAb revealed that blockade of either ICAM-1 or CD11/18 inhibited transmigration, while antibodies against VCAM-1 and VLA-4 had no inhibitory effect. Among antibodies which block beta 2 integrins, anti-CD18 mAb had the best inhibitory effect (88% inhibition). The combined inhibitory effect of anti-CD11a mAb and anti-CD11b mAb was roughly equal to that of anti-CD18, although anti-CD11a (31% inhibition) and anti-CD11b (52% inhibition) were less effective individually. Anti-ICAM-1 by itself inhibited IL-1 beta-induced eosinophil transendothelial migration (24% inhibition) whereas neither anti-E-selectin nor anti-VCAM-1 were effective inhibitors. Interestingly, the combination of anti-E-selectin and anti-VCAM-1 with anti-ICAM-1 inhibited IL-1 beta-induced eosinophil transendothelial migration significantly better (53% inhibition) than anti-ICAM-1 alone. These results suggest that although the initial attachment of eosinophils to IL-1 beta-activated endothelial cells involves VCAM-1, E-selectin, and ICAM-1, the subsequent transendothelial migration process relies heavily on ICAM-1 and CD11/18. Finally, the changes that eosinophils have been observed to undergo during infiltration in vivo, namely increased expression of CD11/18 and shedding of L-selectin, appear to take place as a direct result of the interaction between eosinophils and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1460288

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Intercellular adhesion molecule-1 on eosinophils is involved in eosinophil protein X release induced by cytokines.

Authors:  S Horie; Y Okubo; M Hossain; T Momose; J Suzuki; M Isobe; M Sekiguchi
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane.

Authors:  M W Wakelin; M J Sanz; A Dewar; S M Albelda; S W Larkin; N Boughton-Smith; T J Williams; S Nourshargh
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

3.  Eotaxin increases the expression of CD11b/CD18 and adhesion properties in IL5, but not fMLP-prestimulated human peripheral blood eosinophils.

Authors:  J Lundahl; A Moshfegh; R Grönneberg; G Halldén
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

Review 4.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

5.  Hydrogen peroxide augments eosinophil adhesion via beta2 integrin.

Authors:  M Nagata; H Yamamoto; M Shibasaki; Y Sakamoto; H Matsuo
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

6.  Allergen-stimulated T lymphocytes from allergic patients induce vascular cell adhesion molecule-1 (VCAM-1) expression and IL-6 production by endothelial cells.

Authors:  Y Delneste; P Jeannin; P Gosset; P Lassalle; E Cardot; I Tillie-Leblond; M Joseph; J Pestel; A B Tonnel
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators.

Authors:  D T Walsh; V B Weg; T J Williams; S Nourshargh
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Effects of monoclonal antibodies to adhesion molecules on eosinophilic myocarditis in Toxocara canis-infected CBA/J mice.

Authors:  S Hokibara; M Takamoto; M Isobe; K Sugane
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1.

Authors:  J E Sligh; C M Ballantyne; S S Rich; H K Hawkins; C W Smith; A Bradley; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

10.  Anti-inflammatory, immunomodulatory, and heme oxygenase-1 inhibitory activities of ravan napas, a formulation of uighur traditional medicine, in a rat model of allergic asthma.

Authors:  Sajida Abdureyim; Nurmuhammat Amat; Anwar Umar; Halmurat Upur; Benedicte Berke; Nicholas Moore
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.